Intersect ENT Company Profile (NASDAQ:XENT)

About Intersect ENT

Intersect ENT logoIntersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XENT
  • CUSIP:
Key Metrics:
  • Previous Close: $15.61
  • 50 Day Moving Average: $15.25
  • 200 Day Moving Average: $15.52
  • 52-Week Range: $11.88 - $23.13
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -23.30
  • P/E Growth: 0.12
  • Market Cap: $444.17M
  • Outstanding Shares: 28,454,000
  • Beta: 1.01
  • Net Margins: -42.97%
  • Return on Equity: -23.31%
  • Return on Assets: -21.08%
  • Current Ratio: 12.07%
  • Quick Ratio: 11.52%
Additional Links:
Companies Related to Intersect ENT:

Analyst Ratings

Consensus Ratings for Intersect ENT (NASDAQ:XENT) (?)
Ratings Breakdown: 1 Hold Rating, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: $24.78 (58.73% upside)

Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)
DateFirmActionRatingPrice TargetDetails
9/23/2016WedbushReiterated RatingOutperform$25.00View Rating Details
8/26/2016Piper Jaffray Cos.Reiterated RatingOverweight$21.00View Rating Details
8/4/2016Canaccord GenuityReiterated RatingBuy$20.00View Rating Details
8/4/2016BTIG ResearchReiterated RatingHold$14.00View Rating Details
3/29/2016Northland SecuritiesInitiated CoverageOutperform$26.00View Rating Details
3/24/2016Leerink SwannReiterated RatingBuyView Rating Details
3/24/2016Cantor FitzgeraldReiterated RatingBuy$29.00View Rating Details
12/18/2015Bank of America Corp.Initiated CoverageBuy$26.00View Rating Details
10/2/2015Sterne Agee CRTReiterated RatingBuy$37.00View Rating Details
6/4/2015JPMorgan Chase & Co.Boost Price TargetOverweight$28.00 -> $37.00View Rating Details
4/8/2015CRT CapitalInitiated CoverageBuy$32.00View Rating Details
12/11/2014William BlairInitiated CoverageOutperformView Rating Details
(Data available from 9/29/2014 forward)


Earnings History for Intersect ENT (NASDAQ:XENT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2016Q216($0.26)($0.21)$18.91 million$19.30 millionViewN/AView Earnings Details
5/5/2016Q116($0.29)($0.29)$16.92 million$16.69 millionViewN/AView Earnings Details
2/23/2016Q415($0.25)($0.20)$18.36 million$18.80 millionViewListenView Earnings Details
11/4/2015Q315($0.29)($0.35)$14.80 million$14.20 millionViewN/AView Earnings Details
8/5/2015Q215($0.26)($0.23)$14.74 million$15.20 millionViewN/AView Earnings Details
5/6/2015Q115($0.33)($0.23)$13.00 million$13.37 millionViewN/AView Earnings Details
2/26/2015Q414($0.29)($0.16)$12.20 million$13.40 millionViewN/AView Earnings Details
11/5/2014Q314($0.35)($0.32)$8.20 million$9.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intersect ENT (NASDAQ:XENT)
Current Year EPS Consensus Estimate: $-0.96 EPS
Next Year EPS Consensus Estimate: $-0.67 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($0.31)($0.14)($0.27)
Q2 20165($0.29)($0.12)($0.24)
Q3 20163($0.32)($0.25)($0.27)
Q4 20163($0.20)($0.15)($0.18)
Q1 20171($0.25)($0.25)($0.25)
Q2 20171($0.21)($0.21)($0.21)
Q3 20171($0.28)($0.28)($0.28)
Q4 20171($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)


Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Intersect ENT (NASDAQ:XENT)
Insider Ownership Percentage: 13.90%
Institutional Ownership Percentage: 77.80%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/7/2016Amy WolbeckVPSell28,664$15.83$453,751.12View SEC Filing  
9/6/2016James StambaughVPSell4,000$16.00$64,000.00View SEC Filing  
8/3/2016James StambaughVPSell3,977$17.00$67,609.00View SEC Filing  
7/18/2016James StambaughVPSell5,000$15.33$76,650.00View SEC Filing  
6/13/2016James StambaughVPSell500$14.38$7,190.00View SEC Filing  
5/16/2016Kieran GallahueDirectorBuy8,000$12.64$101,120.00View SEC Filing  
4/27/2016Amy WolbeckVPSell2,000$20.01$40,020.00View SEC Filing  
4/20/2016Richard E KaufmanCOOSell3,603$18.86$67,952.58View SEC Filing  
4/18/2016Lisa D EarnhardtCEOSell28,500$18.69$532,665.00View SEC Filing  
3/21/2016Richard E KaufmanCOOSell3,603$16.51$59,485.53View SEC Filing  
3/15/2016Lisa D EarnhardtCEOSell9,000$18.01$162,090.00View SEC Filing  
3/14/2016Frederic H MollDirectorSell1,299$18.53$24,070.47View SEC Filing  
3/8/2016Frederic H MollDirectorSell601$18.56$11,154.56View SEC Filing  
2/22/2016Richard E KaufmanCOOSell3,603$18.65$67,195.95View SEC Filing  
1/21/2016Richard E. KaufmanCOOSell7,206$17.93$129,203.58View SEC Filing  
1/15/2016Lisa D. EarnhardtCEOSell12,500$19.26$240,750.00View SEC Filing  
12/15/2015Lisa D EarnhardtCEOSell6,820$19.85$135,377.00View SEC Filing  
11/16/2015Lisa D EarnhardtCEOSell6,818$18.00$122,724.00View SEC Filing  
10/15/2015Lisa D EarnhardtCEOSell6,818$18.72$127,632.96View SEC Filing  
9/15/2015Lisa D EarnhardtCEOSell6,818$25.99$177,199.82View SEC Filing  
9/11/2015Frederic H MollDirectorSell10,000$25.21$252,100.00View SEC Filing  
8/17/2015Lisa D EarnhardtCEOSell6,818$28.51$194,381.18View SEC Filing  
7/20/2015James StambaughVPSell12,000$30.52$366,240.00View SEC Filing  
7/15/2015Lisa D EarnhardtCEOSell19,318$29.62$572,199.16View SEC Filing  
6/15/2015Lisa D EarnhardtCEOSell19,318$29.30$566,017.40View SEC Filing  
5/8/2015James StambaughVPSell2,785$23.87$66,477.95View SEC Filing  
4/13/2015Amy WolbeckVPSell16,000$26.25$420,000.00View SEC Filing  
4/1/2015James StambaughVPSell8,343$25.50$212,746.50View SEC Filing  
3/16/2015Lisa D EarnhardtInsiderSell19,318$23.56$455,132.08View SEC Filing  
3/11/2015Amy WolbeckVPSell8,000$23.06$184,480.00View SEC Filing  
3/9/2015James StambaughVPSell8,343$23.02$192,055.86View SEC Filing  
2/17/2015Lisa D EarnhardtInsiderSell19,318$22.69$438,325.42View SEC Filing  
2/12/2015Amy WolbeckVPSell8,000$22.12$176,960.00View SEC Filing  
2/2/2015James StambaughVPSell8,343$20.98$175,036.14View SEC Filing  
1/26/2015Robert H Binney JrVPSell6,300$21.18$133,434.00View SEC Filing  
9/11/2014Cynthia L LuccheseDirectorBuy5,000$17.11$85,550.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Intersect ENT (NASDAQ:XENT)
News IconIntersect ENT, Inc. (XENT) – Broker Update - NewsDen (NASDAQ:XENT) - September 29 at 5:50 AM logoIntersect ENT, Inc. (NASDAQ:XENT) Stock Rating Update - Investor Newswire (NASDAQ:XENT) - September 19 at 3:15 PM logoIntersect ENT, Inc. (NASDAQ:XENT) Stock Rating Update - Investor Newswire (NASDAQ:XENT) - September 19 at 3:15 PM logoIntersect ENT Announces American Rhinologic Society Endorsement of the Use of Drug Eluting Sinus Implants (NASDAQ:XENT) - September 19 at 3:15 PM logoExpected For Intersect ENT, Inc. (NASDAQ:XENT) Sales Of $141.05 - Investor Newswire (NASDAQ:XENT) - September 14 at 8:24 PM logoIntersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : September 14, 2016 (NASDAQ:XENT) - September 14 at 8:24 PM logoIntersect ENT, Inc. breached its 50 day moving average in a Bullish Manner : XENT-US : September 13, 2016 (NASDAQ:XENT) - September 14 at 12:34 PM
News IconStock Update: Estimates & Target in Focus for Intersect ENT, Inc. (NASDAQ:XENT) - Frisco Fastball (NASDAQ:XENT) - September 10 at 5:46 AM
News IconPlacing Intersect ENT, Inc. (NASDAQ:XENT) Shares Under the Microscope - Post News (NASDAQ:XENT) - September 8 at 7:47 PM logoIntersect ENT (XENT) Notes Positive CareFirst BlueCross BlueShield Coverage Determination for PROPEL - (NASDAQ:XENT) - August 29 at 8:16 PM logoIntersect ENT Announces Positive Coverage Decision by CareFirst BlueCross BlueShield to Expand Access to PROPEL Steroid Releasing Implants to More Patients (NASDAQ:XENT) - August 29 at 8:16 PM
News IconIntersect ENT Inc. (NASDAQ: XENT) Stock Rating Reiterated at ... - BNB Daily (blog) (NASDAQ:XENT) - August 29 at 5:52 AM logoIntersect ENT, Inc. (NASDAQ:XENT) Reports Sales Of $19.317, Surprising Estimates By 0.036% - Investor Newswire (NASDAQ:XENT) - August 24 at 8:05 PM logoWill Intersect ENT, Inc. (NASDAQ:XENT) Hit $26 Price Target? - Investor Newswire (NASDAQ:XENT) - August 22 at 5:37 AM
News IconWhat is the Sell-side Saying About Intersect ENT, Inc. (NASDAQ:XENT)? - Post News (NASDAQ:XENT) - August 18 at 8:33 PM logoAnalysts See Sales Of $141.05 For Intersect ENT, Inc. (NASDAQ:XENT) - Investor Newswire (NASDAQ:XENT) - August 18 at 11:31 AM logoINTERSECT ENT, INC. Financials (NASDAQ:XENT) - August 16 at 8:27 PM logoETF’s with exposure to Intersect ENT, Inc. : August 11, 2016 (NASDAQ:XENT) - August 11 at 9:00 PM logoIntersect ENT, Inc. :XENT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:XENT) - August 10 at 9:06 PM logoNewly released market study: Intersect ENT Inc. (XENT) - Medical Equipment - Deals and Alliances Profile (NASDAQ:XENT) - August 10 at 11:38 AM logoINTERSECT ENT, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:XENT) - August 8 at 8:35 PM logoStrong Sell Calls For Intersect ENT, Inc. (NASDAQ:XENT) At 0 - Investor Newswire (NASDAQ:XENT) - August 8 at 5:40 AM
News IconIntersect ENT Reports Second Quarter 2016 Results (NASDAQ:XENT) - August 3 at 11:42 AM logoEdited Transcript of XENT earnings conference call or presentation 2-Aug-16 8:30pm GMT (NASDAQ:XENT) - August 3 at 11:42 AM logoIntersect ENT reports 2Q loss (NASDAQ:XENT) - August 2 at 8:46 PM logoIntersect ENT (XENT) Submits Supplemental PMAs for NOVA ... - (NASDAQ:XENT) - August 2 at 5:46 AM logoIntersect ENT Announces FDA Submission of NOVA Bioabsorbable Steroid Releasing Implant for Patients With Chronic Sinus Disease (NASDAQ:XENT) - August 1 at 8:07 PM logoWill Intersect ENT, Inc. (NASDAQ:XENT) Surprise Analysts? - Investor Newswire (NASDAQ:XENT) - July 31 at 7:36 PM logoIs $37 Price Target Attainable For Intersect ENT, Inc. (NASDAQ:XENT)? - Investor Newswire (NASDAQ:XENT) - July 25 at 5:49 AM logoBroker Outlook For Intersect ENT, Inc. (XENT) - Fiscal Standard (NASDAQ:XENT) - July 22 at 11:17 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Intersect ENT, Inc. (NASDAQ:XENT) - TGP (NASDAQ:XENT) - July 21 at 8:43 PM logoIntersect ENT, Inc. (NASDAQ:XENT) Expected To Post Sales Of $151.35 - Investor Newswire (NASDAQ:XENT) - July 21 at 11:11 AM
News IconTrading Performance and Target Watch for Intersect ENT, Inc. (NASDAQ:XENT) - Press Telegraph (NASDAQ:XENT) - July 20 at 9:29 PM
News IconInvestor Watch: Volatility Recap on Shares of: Intersect ENT, Inc. (NASDAQ:XENT) - Engelwood Daily (NASDAQ:XENT) - July 20 at 9:29 PM
News IconIntersect ENT, Inc. (NASDAQ:XENT): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:XENT) - July 20 at 9:29 PM
News IconIs Intersect ENT Inc. (NASDAQ: XENT) Trying To Pull A Fast One On Investors? - Scibility Media (NASDAQ:XENT) - July 20 at 9:29 PM logoIntersect ENT Announces Preliminary Q2 Figures, Stock Up (NASDAQ:XENT) - July 20 at 9:32 AM
News IconIntersect ENT (Nasdaq: $XENT) Announces Preliminary Q2 Revenue and Business Update (NASDAQ:XENT) - July 19 at 8:33 PM logoIntersect ENT Schedules Second Quarter 2016 Earnings Release and Conference Call for August 2, 2016 (NASDAQ:XENT) - July 19 at 4:05 PM logoETF’s with exposure to Intersect ENT, Inc. : July 19, 2016 (NASDAQ:XENT) - July 19 at 1:25 PM logoINTERSECT ENT, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Princip (NASDAQ:XENT) - July 18 at 4:41 PM logoIntersect ENT, Inc. breached its 50 day moving average in a Bullish Manner : XENT-US : July 15, 2016 (NASDAQ:XENT) - July 15 at 8:25 AM logoIntersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease (NASDAQ:XENT) - July 12 at 10:49 AM logoNotable Tuesday Option Activity: GTLS, XENT, FEYE (NASDAQ:XENT) - June 23 at 9:09 PM logoINTERSECT ENT, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:XENT) - June 7 at 4:10 PM logoIntersect ENT to Present at William Blair & Company 36th Annual Growth Stock Conference (NASDAQ:XENT) - June 2 at 4:05 PM logoIntersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis (NASDAQ:XENT) - June 1 at 8:00 AM logoIntersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : March 10, 2016 (NASDAQ:XENT) - March 10 at 1:20 PM logoIntersect ENT, Inc. breached its 50 day moving average in a Bearish Manner : XENT-US : March 9, 2016 (NASDAQ:XENT) - March 9 at 8:11 AM logoINTERSECT ENT, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib (NASDAQ:XENT) - February 26 at 4:56 PM


Intersect ENT (NASDAQ:XENT) Chart for Thursday, September, 29, 2016

Last Updated on 9/29/2016 by Staff